These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 33837910

  • 1. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
    Gutierrez-Sainz L, Cruz P, Martinez-Recio S, Higuera O, Esteban-Rodriguez MI, Arias-Lotto F, Gonzalez RA, De Castro-Carpeño J.
    Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb 01; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 01; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 9. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct 01; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 10. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
    Zhang F, Gong W.
    Int Immunopharmacol; 2020 Jun 01; 83():106481. PubMed ID: 32339986
    [Abstract] [Full Text] [Related]

  • 11. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 01; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 12. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun 01; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 13. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May 01; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 14. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.
    Mol Biol Rep; 2019 Jun 01; 46(3):2713-2720. PubMed ID: 30840203
    [Abstract] [Full Text] [Related]

  • 15. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, Volante M, Scagliotti GV.
    Clin Lung Cancer; 2021 Jan 01; 22(1):e63-e66. PubMed ID: 32917522
    [Abstract] [Full Text] [Related]

  • 16. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.
    Lung Cancer; 2016 Jun 01; 96():1-6. PubMed ID: 27133741
    [Abstract] [Full Text] [Related]

  • 17. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP.
    J Cancer Res Clin Oncol; 2021 Feb 01; 147(2):459-468. PubMed ID: 33216211
    [Abstract] [Full Text] [Related]

  • 18. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods.
    Sule Kutlar Dursun F, Alabalik U.
    Pol J Pathol; 2022 Feb 01; 73(2):111-119. PubMed ID: 36172747
    [Abstract] [Full Text] [Related]

  • 19. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB, Ozturk A, Mutlu H.
    Asian Pac J Cancer Prev; 2014 Feb 01; 15(5):2061-7. PubMed ID: 24716935
    [Abstract] [Full Text] [Related]

  • 20. Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma.
    Okita R, Senoo T, Mimura-Kimura Y, Mimura Y, Murakami T, Ikeda E, Okada M, Inokawa H, Aoe K.
    Sci Rep; 2024 Jul 10; 14(1):15947. PubMed ID: 38987362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.